1. Nanocarriers for anticancer drugs: Challenges and perspectives;Alqosaibi AI;Saudi J Biol Sci,2022
2. aC. Carvalho SRX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI Doxorubicin: the good, the bad and the ugly effect. Current medicinal chemistry 16: 3267–3285., Wenningmann bN, Ande KM, Vaidya A, Ait-Oudhia TR (2009) S. (2019) Insights into doxorubicin-induced cardiotoxicity: molecular mechanisms, preventive strategies, and early monitoring. Molecular pharmacology 96: 219–232. https://doi.org/10.1124/mol.119.115725
3. Inhibition of carbonyl reductase 1 safely improves the efficacy of doxorubicin in breast cancer treatment;Jo A;Antioxid Redox Signal,2017
4. aE. Rahmani PM, Ghorbanian SA, Yazdian F, Rashedi H, Navaee M Preparation of a pH-responsive chitosan-montmorillonite-nitrogen-doped carbon quantum dots nanocarrier for attenuating doxorubicin limitations in cancer therapy. Engineering in life sciences 22: 634–649., bB. Shankar JP, Saikrishna B, Perugu S, Manga V (2022) (2018) Synthesis, anti-microbial activity, cytotoxicity of some novel substituted (5-(3-(1H-benzo[d]imidazol-2-yl)-4-hydroxybenzyl)benzofuran-2-yl)(phenyl)methanone analogs. Chemistry Central journal 12: 1. https://doi.org/10.1186/s13065-017-0364-3
5. Butowska K, Woziwodzka A, Borowik A, Piosik J (2021) Polymeric Nanocarriers: A Transformation in Doxorubicin Therapies. Materials (Basel, Switzerland) 14. http://dx.doi.org/10.20944/preprints202103.0095.v1